Somewhat Favorable News Coverage Somewhat Unlikely to Impact Dextera Surgical (DXTR) Stock Price
News headlines about Dextera Surgical (NASDAQ:DXTR) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dextera Surgical earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 46.4883840282481 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Analysts Sights: Dextera Surgical Inc (DXTR)Expert Gazette | Expert … – ExpertGazette (expertgazette.com)
- Dextera Surgical Inc (DXTR) Given $0.75 Consensus Target Price by Analysts – ExpertGazette (expertgazette.com)
- Breakfast Technical Briefing on Medical Supplies Stocks — Endologix, Dextera Surgical, Becton, Dickinson, and Ekso Bionics (bizjournals.com)
- $880,000.00 in Sales Expected for Dextera Surgical Inc. (DXTR) This Quarter (americanbankingnews.com)
- Dextera Surgical Inc. (NASDAQ:DXTR) – Active Stock Evaluation – Nasdaq Journal (press release) (nasdaqjournal.com)
Dextera Surgical (NASDAQ DXTR) opened at $0.15 on Friday. Dextera Surgical has a 52 week low of $0.11 and a 52 week high of $2.33.
Dextera Surgical (NASDAQ:DXTR) last released its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.62 million. sell-side analysts anticipate that Dextera Surgical will post -0.25 EPS for the current fiscal year.
Several analysts have commented on the company. Zacks Investment Research downgraded Dextera Surgical from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Ladenburg Thalmann Financial Services started coverage on Dextera Surgical in a research note on Wednesday, August 16th. They issued a “buy” rating and a $0.80 price target on the stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-dextera-surgical-dxtr-stock-price/1727515.html.
About Dextera Surgical
Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.
Receive News & Ratings for Dextera Surgical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.